Last reviewed · How we verify
Oratecan and Capecitabine
At a glance
| Generic name | Oratecan and Capecitabine |
|---|---|
| Also known as | Oratecan(HM30181AK + Irinotecan HCl) and Capecitabine |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oratecan and Capecitabine CI brief — competitive landscape report
- Oratecan and Capecitabine updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI